QuidelOrtho Corporation (QDEL)

Market Cap	908.62M -52.1%
Revenue (ttm)	2.67B -2.5%
Net Income	-1.05B
EPS	-15.40
Shares Out	68.58M
PE Ratio	n/a
Forward PE	12.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,737,545
Open	13.45
Previous Close	13.76
Day's Range	12.48 - 13.51
52-Week Range	9.92 - 35.58
Beta	0.78
Analysts	Hold
Price Target	14.67 (+10.72%)
Earnings Date	Nov 3, 2026

About QDEL

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1979
• Employees: 6,500
• Stock Exchange: Nasdaq
• Ticker Symbol: QDEL
• Website: https://www.quidelortho.com

Financial Performance

In 2025, QuidelOrtho's revenue was $2.73 billion, a decrease of -1.89% compared to the previous year's $2.78 billion. Losses were -$1.13 billion, -44.84% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for QDEL stock is "Hold." The 12-month stock price target is $14.67, which is an increase of 10.72% from the latest price.

Price Target

$14.67

(10.72% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 31, 2026

Data Sources Report a data error